Literature DB >> 23983447

Favorable effect of modest alcohol consumption to fatty liver disease.

Masahide Hamaguchi, Takao Kojima.   

Abstract

We previously reported that modest alcohol consumption was significantly inversely associated with fatty liver disease. Feng et al pointed out a discrepancy of statistical significance between our current larger scale cohort and a previous cohort. However, the prevalence of non-alcoholic fatty liver disease was higher in non or minimal drinkers than those in light drinkers in both cohorts. They also argue that some potential co-factors such as soft drink consumption and genetic variations should be discussed.

Entities:  

Keywords:  Alcohol; Diabetes; Fatty liver disease; Metabolic syndrome; Obesity

Mesh:

Year:  2013        PMID: 23983447      PMCID: PMC3752578          DOI: 10.3748/wjg.v19.i32.5393

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  13 in total

1.  Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study.

Authors:  Joanna Raszeja-Wyszomirska; Grzegorz Kurzawski; Malgorzata Lawniczak; Joanna Miezynska-Kurtycz; Jan Lubinski
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

Authors:  Ahmad Al-Serri; Quentin M Anstee; Luca Valenti; Valerio Nobili; Julian B S Leathart; Paola Dongiovanni; Julia Patch; Anna Fracanzani; Silvia Fargion; Christopher P Day; Ann K Daly
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

3.  Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia.

Authors:  Ayako Suzuki; Paul Angulo; Jennifer St Sauver; Ayako Muto; Toshihide Okada; Keith Lindor
Journal:  Am J Gastroenterol       Date:  2007-05-17       Impact factor: 10.864

4.  Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population.

Authors:  Toshiaki Gunji; Nobuyuki Matsuhashi; Hajime Sato; Kazutoshi Fujibayashi; Mitsue Okumura; Noriko Sasabe; Akio Urabe
Journal:  Am J Gastroenterol       Date:  2009-06-23       Impact factor: 10.864

5.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

6.  Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.

Authors:  Johannes-W Rey; Andrea Noetel; Aline Hardt; Ali Canbay; Hakan Alakus; Axel Zur Hausen; Hans-Peter Dienes; Uta Drebber; Margarete Odenthal
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

7.  Soft drinks consumption and nonalcoholic fatty liver disease.

Authors:  William Nseir; Fares Nassar; Nimer Assy
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

8.  Protective effect of alcohol consumption for fatty liver but not metabolic syndrome.

Authors:  Masahide Hamaguchi; Takao Kojima; Akihiro Ohbora; Noriyuki Takeda; Michiaki Fukui; Takahiro Kato
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

9.  Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Ali Hariri; Carol Nelson-Williams; Jia Nee Foo; Xian-Man Zhang; James Dziura; Richard P Lifton; Gerald I Shulman
Journal:  N Engl J Med       Date:  2010-03-25       Impact factor: 91.245

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.